Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM).

Thomas Cluzeau,Marie Sebert,Ramy Rahme,Stefania Cuzzubbo,Jacqueline Lehmann-Che,Isabelle Madelaine,Pierre Peterlin,Blandine Beve,Habiba Attalah,Fatiha Chermat,Elsa Miekoutima,Odile Beyne-Rauzy,Christian Recher,Aspasia Stamatoullas,Lise Willems,Emmanuel Raffoux,Céline Berthon,Bruno Quesnel,Michael Loschi,Antoine F. Carpentier,David A. Sallman,Rami S. Komrokji,Anouk Walter-Petrich,Sylvie Chevret,Lionel Ades,Pierre Fenaux

Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM).

2021

PURPOSETP53-mutated (TP53m) myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) have very poor outcome irrespective of the treatment received, including 40% responses (20% complete rem...

Keywords:

Oncology
Azacitidine
Myeloid leukemia
Medicine
Phases of clinical research
Internal medicine
Myelodysplastic syndromes

Correction
Source
Cite
Save

References

Citations